NCT05203640Recruiting
Effects of Resistance Exercise on Blood Glucose in Post-menopausal Women With Type 1 Diabetes
Acute Glycemic Effects of Resistance Exercise in Post-menopausal Women With Type 1 Diabetes
Source: ClinicalTrials.gov · Last updated 8 Jul 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Regular physical activity has substantial health benefits in people with type 1 diabetes. The fear of hypoglycemia, both during and after exercise, is a major barrier to exercise in this population. A major obstacle to providing specific physical activity and exercise advice is that there are still significant gaps in the fundamental understanding of the impact of physical activity and exercise on blood glucose levels in type 1 diabetes. Women with type 1 diabetes have a substantial increase in cardiovascular risk once they have passed menopause. They may lose both bone quality and muscle mass at a faster rate with aging than those without diabetes. Overall, these changes greatly increase the risk of both cardiovascular and frailty related complications. Despite the many potential benefits of resistance exercise for post-menopausal women with type 1 diabetes, there are currently no published studies examining the effects of resistance exercise in this population. Before being able to design a clinical trial of resistance exercise, an examination of the acute effects of resistance exercise on blood glucose levels in post-menopausal women with type 1 diabetes is required. The present study will compare the glycemic effects of a low resistance, high repetition (3 sets of 15 to 20 repetitions) weight lifting program to the effects of a moderate resistance, moderate repetition (3 sets of 8 to 10 repetitions). The investigators hypothesize that the high repetition program will be associated with a bigger decline in blood glucose during exercise, but that the moderate resistance program will be associated with a higher risk of post-exercise hypoglycemia.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 16 (estimated)
- First submitted
- 10 Jan 2022
- Start date
- 1 Apr 2022
- Primary completion date
- 30 Jun 2026
- Lead sponsor
- University of Alberta
- Diseases
- Type 1 diabetes
- NCT number
- NCT05203640
What you commit to
- Study type: Interventional
- Planned participants: 16
- From 1 Apr 2022 to the primary completion date, 30 Jun 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- A history of cardiovascular disease
Lab values
- Individuals with HbA1c \>9.9%
- Individuals who are treated with medications (other than insulin) that affect glucose metabolism (e.g. atypical antipsychotics, corticosteroids)
Other
- Frequent and unpredictable hypoglycaemia
- A change in insulin management strategy within two months of the study
- Blood pressure \> 144/95,
- Severe peripheral neuropathy,
- Musculoskeletal injuries affecting the ability to perform resistance exercise.
- A body mass index \>30kg/m2,
- Smoking
- Moderate to high alcohol intake (\>2 drinks per day)
Who the study is looking for
- female
- type 1 diabetes diagnosed for at least 1 year
- at least 12 months since last menstrual period
- physically able and willing to perform resistance exercise
- HbA1c \< 10%
- residing near Edmonton, Alberta / able to attend laboratory based sessions at the University of Alberta
Age in the registry: 45 years to 75 years · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Alberta Diabetes Institute Coordinator of this site? Confirm its status | Edmonton | Canada | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.